1. Progression of liver fibrosis following acute hepatitis C virus infection in HIV-positive MSM
- Author
-
Newsum, A.M., Kooij, K.W., Boyd, A., Smit, C., Wit, F.W.N.M., Meer, J.T.M. van der, Prins, M., Reiss, P., Valk, M. van der, Eden, H. van, Molenkamp, R., Pijnappel, F., Reesink, H.W., Schinkel, J., Steba, G.S., Berk, G.E.L. van den, Brinkman, K., Hooijenga, I., Kwa, D., Meche, N. van der, Toonen, A., Vos, D., Broekhuizen, M. van, Lauw, E.N., Mulder, J.W., Arend, J.E., Kessel, A. van, Silvius, B., Versloot, M., Boonstra, A., Rijnders, B.J.A., Brokking, W., Eeden, A. van, Elsenburg, L., Nobel, H.E., Laar, T.J.W. van de, Veldt, W. van der, Geerlings, S.E., Goorhuis, A., Hovius, J.W., Lempkes, B., Nellen, F.J.B., Poll, T. van der, Prins, J.M., Vugt, M. van, Wiersinga, W.J., Duinen, M. van, Eden, J. van, Hazenberg, A., Hes, A.M.H. van, Pijnappel, F.J.J., Smalhout, S.Y., Weijsenfeld, A.M., Jurriaans, S., Back, N.K.T., Zaaijer, H.L., Berkhout, B., Cornelissen, M.T.E., Schinkel, C.J., Wolthers, K.C., Peters, E.J.G., Agtmael, M.A. van, Bomers, M., Sigaloff, K.C.E., Heitmuller, M., Laan, L.M., Ang, C.W., Houdt, R. van, Jonges, M., Pettersson, A.M., Prehn, J. van, Berge, M. van den, Stegeman, A., Baas, S., Looff, L.H. de, Wintermans, B., Veenemans, J., Pronk, M.J.H., Ammerloan, H.S.M., Munnik, E.S. de, Jansz, A.R., Tjhie, J., Wegdam, M.C.A., Deiman, B., Scharnhorst, V., Elsenburg, L.J.M., Nobel, H., Damen, M., Kasteren, M.E.E. van, Berrevoets, M.A.H., Brouwer, A.E., Adams, A., Kruijf-van de Wiel, B.A.E. de, Keelan-Pfaf, S., Ven, B. van de, Ven, B. van der, Buiting, A.G.M., Murck, J.L., Versteeg, D., Ende, M.E. van der, Box, H.I., Gorp, E.C.M. van, Nouwen, J.L., Schurink, C.A.M., Verbon, A., Vries-Sluijs, T.E.M.S. de, Jong-Peltenburg, N.C. de, Bassant, N., Beek, J.E.A. van, Vriesde, M., Zonneveld, L.M. van, Berg-Cameron, H.J. van den, Groot, J. de, Boucher, C.A.B., Koopmans, M.P.G., Kampen, J.J.A. van, Branger, J., Douma, R.A., Duijf-van de Ven, C.J.H.M., Schippers, E.F., Nieuwkoop, C. van, IJperen, J.M. van, Geilings, J., Hut, G. van der, Burgel, N.D. van, Leyten, E.M.S., Gelinck, L.B.S., Mollema, F., Davids-Veldhuis, S., Hartingsveld, A.Y. van, Wildenbeest, G.S., Heikens, E., Groeneveld, P.H.P., Bouwhuis, J.W., Lammers, A.J.J., Kraan, S., Hulzen, A.G.W. van, Kruiper, M.S.M., Bliek, G.L. van der, Bor, P.C.J., Bloembergen, P., Wolthagen, M.H.M., Ruijs, G.J.H.M., Kroon, E., Boer, M.G.J. de, Scheper, H., Jolink, H., Dorama, W., Holten, N. van, Claas, E.C.J., Wessels, E., Hollander, J.G. den, Pogany, K., Roukens, A., Douma, R., Kastelijns, M., Smit, J.V., Smit, E., Struik-Kalkman, D., Tearno, C., Niekerk, T. van, Pontesilli, O., Lowe, S.H., Lashof, A.M.L.O., Posthouwer, D., Ackens, R.P., Burgers, K., Schippers, J., Enberg-Maes, B.W., Loo, I.H.M. van, Havenith, T.R.A., Vrouenraets, S.M.E., Broekhuizen, M.C. van, Vlasblom, D.J., Kroeze, M., Smits, P.H.M., Weijer, S., Moussaoui, R. el, Bosma, A.S., Vonderen, M.G.A. van, Kampschreur, L.M., Faber, S., Steeman-Bouma, R., Wed, J., Kootstra, G.J., Delsing, C.E., Burg-van de Plas, M. van der, Heins, H., Kortmann, W., Twillert, G. van, Renckens, R., Ruiter-Pronk, D., Truijen-Oud, E.A. van, Stuart, J.W.T.C., Jansen, E.R., Hoogewerf, M., Rozemeijer, W., Reijden, W.A. van der, Sinnige, J.C., Blok, W.L., Frissen, P.H.J., Lettinga, K.D., Schouten, W.E.M., Veenstra, J., Brouwer, C.J., Geerders, G.E., Hoeksema, K., Kleene, M.J., Knapen, M., Meche, I.B. van der, Mulder-Seeleman, E., Toonen, A.J.M., Wijnands, S., Crevel, R. van, Dofferhoff, A.S.M., Hofstede, H.J.M. ter, Hoogerwerf, J., Keuter, M., Richel, O., Albers, M., Grintjes-Huisman, K.J.T., Haan, M. de, Marneef, M., Strik-Albers, R., Rahamat-Langendoen, J., Stelma, E.E., Burger, D., Gisolf, E.H., Hassing, R.J., Claassen, M., Beest, G. ter, Bentum, P.H.M. van, Langebeek, N., Tiemessen, R., Swanink, C.M.A., Lelyveld, S.F.L. van, Soetekouw, R., Prijt, L.M.M. van der, Swaluw, J. van der, Bermon, N., Jansen, R., Herpers, B.L., Veenendaal, D., Verhagen, D.W.M., Wijk, M. van, Bierman, W.F.W., Bakker, M., Kleinnij, APH - Global Health, AII - Infectious diseases, Graduate School, Infectious diseases, APH - Aging & Later Life, Global Health, APH - Methodology, APH - Digital Health, APH - Personalized Medicine, Gastroenterology & Hepatology, Internal Medicine, Virology, Medical Microbiology & Infectious Diseases, Med Microbiol, Infect Dis & Infect Prev, MUMC+: DA MMI Staf (9), RS: CAPHRI - R4 - Health Inequities and Societal Participation, MUMC+: TPZ Verpleegkundig Team Infectieziekten (9), MUMC+: DA MMI Infectieserologie (9), MUMC+: DA MMI AIOS (9), MUMC+: DA KFT Medische Staf (9), Anatomy and neurosciences, Amsterdam Movement Sciences - Rehabilitation & Development, Internal medicine, and Microbes in Health and Disease (MHD)
- Subjects
Liver Cirrhosis ,Male ,0301 basic medicine ,HIV Infections ,Disease ,DISEASE ,0302 clinical medicine ,ANTIRETROVIRAL THERAPY ,STAGE ,Interquartile range ,HEPATOCELLULAR-CARCINOMA ,Immunology and Allergy ,030212 general & internal medicine ,Immunodeficiency ,Netherlands ,liver fibrosis ,RISK ,education.field_of_study ,IMMUNODEFICIENCY ,Coinfection ,HIV/hepatitis C virus coinfection ,MEN ,Hepatitis C ,Markov Chains ,Infectious Diseases ,Hepatocellular carcinoma ,Disease Progression ,SEX ,Adult ,medicine.medical_specialty ,Population ,Immunology ,acute hepatitis C virus infection ,03 medical and health sciences ,SDG 3 - Good Health and Well-being ,Internal medicine ,medicine ,Humans ,MSM ,Homosexuality, Male ,education ,Retrospective Studies ,Hepatitis ,business.industry ,fibrosis-4 ,Retrospective cohort study ,NONINVASIVE INDEX ,medicine.disease ,Confidence interval ,INDIVIDUALS ,030104 developmental biology ,business - Abstract
Background: Whether continued, accelerated liver fibrosis progression occurs following acute hepatitis C virus infection (AHCVI) in HIV-positive MSM is unknown.Design and methods: HIV-positive MSM from the AIDS Therapy Evaluation in the Netherlands and MSM Observational Study for Acute Infection with Hepatitis C-cohorts with primary AHCVI and at least one fibrosis-4 (FIB-4) measurement less than 2 years before and 1 year after estimated AHCVI were included. Mixed-effect linear models were used to evaluate (time-updated) determinants of FIB-4 levels over time. Determinants of transitioning to and from FIB-4 1.45 were examined using multistate Markov models.Results: Of 313 MSM, median FIB-4 measurements per individual was 12 (interquartile range = 8-18) and median follow-up following AHCVI was 3.5 years (interquartile range = 1.9-5.6). FIB-4 measurements averaged at 1.00 [95% confidence interval (CI) = 0.95-1.05] before AHCVI, 1.31 (95% CI = 1.25-1.38) during the first year of AHCVI and 1.10 (95% CI = 1.05-1.15) more than 1 year after AHCVI. Mean FIB-4 more than 1 year after AHCVI was higher for chronically infected patients compared with those successfully treated (P = 0.007). Overall FIB-4 scores were significantly higher with older age, lower CD4(+) cell count, longer duration from HIV-diagnosis or AHCVI, and nonresponse to HCV-treatment. At the end of follow-up, 60 (19.2%) and eight MSM (2.6%) had FIB-4 between 1.45-3.25 and >= 3.25, respectively. Older age, lower CD4(+) cell count and detectable HIV-RNA were significantly associated with higher rates of progression to FIB-4 > 1.45, whereas older age, longer duration from HIV-diagnosis and nonresponse to HCV-treatment were significantly associated with lower rates of regression to FIB-4Conclusion: In this population of HIV-positive MSM, FIB-4 scores were higher during the first year of AHCVI, but FIB-4 >= 3.25 was uncommon by the end of follow-up. Well controlled HIV-infection appears to attenuate FIB-4 progression. Copyright (C) 2019 Wolters Kluwer Health, Inc. All rights reserved.
- Published
- 2019